156 related articles for article (PubMed ID: 17485025)
1. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation.
Iwai M; Chen R; Imura Y; Horiuchi M
Am J Hypertens; 2007 May; 20(5):579-86. PubMed ID: 17485025
[TBL] [Abstract][Full Text] [Related]
2. Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.
Iwai M; Kanno H; Inaba S; Senba I; Sone H; Nakaoka H; Horiuchi M
Am J Hypertens; 2011 Feb; 24(2):169-74. PubMed ID: 20847723
[TBL] [Abstract][Full Text] [Related]
3. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma.
Zorad S; Dou JT; Benicky J; Hutanu D; Tybitanclova K; Zhou J; Saavedra JM
Eur J Pharmacol; 2006 Dec; 552(1-3):112-22. PubMed ID: 17064684
[TBL] [Abstract][Full Text] [Related]
4. Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models.
Tomono Y; Iwai M; Inaba S; Mogi M; Horiuchi M
Am J Hypertens; 2008 Feb; 21(2):206-12. PubMed ID: 18188158
[TBL] [Abstract][Full Text] [Related]
5. Effects of angiotensin II AT1 receptor inhibition and exercise training on insulin action in rats on high-fat diet.
Wang Z; Koike T; Li P; Jiang H; Natsume Y; Mu L; Chen T; Oshida Y
Life Sci; 2012 Feb; 90(9-10):322-7. PubMed ID: 22210187
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice.
Fujisaka S; Usui I; Kanatani Y; Ikutani M; Takasaki I; Tsuneyama K; Tabuchi Y; Bukhari A; Yamazaki Y; Suzuki H; Senda S; Aminuddin A; Nagai Y; Takatsu K; Kobayashi M; Tobe K
Endocrinology; 2011 May; 152(5):1789-99. PubMed ID: 21427223
[TBL] [Abstract][Full Text] [Related]
7. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
Iwai M; Li HS; Chen R; Shiuchi T; Wu L; Min LJ; Li JM; Tsuda M; Suzuki J; Tomono Y; Tomochika H; Mogi M; Horiuchi M
J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
[TBL] [Abstract][Full Text] [Related]
8. Improvement of glucose intolerance by combination of pravastatin and olmesartan in type II diabetic KK-A(y) mice.
Kanno H; Iwai M; Inaba S; Senba I; Nakaoka H; Sone H; Mogi M; Horiuchi M
Hypertens Res; 2009 Aug; 32(8):706-11. PubMed ID: 19478815
[TBL] [Abstract][Full Text] [Related]
9. Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.
Iwai M; Kanno H; Tomono Y; Inaba S; Senba I; Furuno M; Mogi M; Horiuchi M
J Hypertens; 2010 Jul; 28(7):1471-81. PubMed ID: 20543712
[TBL] [Abstract][Full Text] [Related]
10. Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions.
Wada T; Onogi Y; Kimura Y; Nakano T; Fusanobori H; Ishii Y; Sasahara M; Tsuneki H; Sasaoka T
Eur J Pharmacol; 2013 May; 707(1-3):120-9. PubMed ID: 23528355
[TBL] [Abstract][Full Text] [Related]
11. [Candesartan improves insulin resistance induced by high-fat diet in rats].
Yan WH; Dou JT; Pan CY; Chen K; Wang XM; Ma FL; Yang GQ; Wang XL; Mu YM; Lu JM
Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(38):2695-9. PubMed ID: 19080690
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients.
Koh KK; Quon MJ; Han SH; Chung WJ; Lee Y; Shin EK
Int J Cardiol; 2006 Mar; 108(1):96-100. PubMed ID: 16246439
[TBL] [Abstract][Full Text] [Related]
13. Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice.
Inoue E; Ichiki T; Takeda K; Matsuura H; Hashimoto T; Ikeda J; Kamiharaguchi A; Sunagawa K
J Endocrinol; 2012 Jun; 213(3):285-91. PubMed ID: 22460613
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice.
Shao J; Iwashita N; Ikeda F; Ogihara T; Uchida T; Shimizu T; Uchino H; Hirose T; Kawamori R; Watada H
Biochem Biophys Res Commun; 2006 Jun; 344(4):1224-33. PubMed ID: 16650382
[TBL] [Abstract][Full Text] [Related]
15. Acute treatment with candesartan cilexetil, an angiotensin II type 1 receptor blocker, improves insulin sensitivity in high-fructose-diet-fed rats.
Li P; Koike T; Jiang HY; Wang ZH; Kawata Y; Oshida Y
Horm Metab Res; 2012 Apr; 44(4):286-90. PubMed ID: 22344624
[TBL] [Abstract][Full Text] [Related]
16. Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice.
Ushijima K; Takuma M; Ando H; Ishikawa-Kobayashi E; Nozawa M; Maekawa T; Shiga T; Fujimura A
Eur J Pharmacol; 2013 Jan; 698(1-3):505-10. PubMed ID: 23195328
[TBL] [Abstract][Full Text] [Related]
17. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
Minoura H; Takeshita S; Kimura C; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Mutoh S
Diabetes Obes Metab; 2007 May; 9(3):369-78. PubMed ID: 17391165
[TBL] [Abstract][Full Text] [Related]
18. Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan.
Tsukuda K; Mogi M; Li JM; Iwanami J; Min LJ; Sakata A; Fujita T; Iwai M; Horiuchi M
Hypertension; 2007 Dec; 50(6):1099-105. PubMed ID: 17968000
[TBL] [Abstract][Full Text] [Related]
19. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
20. Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes.
Tian F; Luo R; Zhao Z; Wu Y; Ban Dj
Exp Clin Endocrinol Diabetes; 2010 Apr; 118(4):258-65. PubMed ID: 19856251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
